Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fullerenol-C60 is a water-soluble derivative of the carbon-60 (C60) fullerene molecule that has been functionalized with multiple hydroxyl (-OH) groups. This modification enhances its solubility in water and biological systems. Fullerenol-C60 exhibits strong antioxidant properties by scavenging free radicals such as superoxide anion and hydroxy radical. It can also interact with reactive oxygen species (ROS), providing cytoprotective effects against oxidative stress in various tissues. Preclinical studies have demonstrated its potential to reduce oxidative and histopathological damage in organs such as lungs, kidneys, and skeletal muscle following ischemia-reperfusion injury. Additionally, it shows promise for use as an anti-inflammatory agent and may have antiviral activity against influenza viruses. Its unique structure allows for applications across pharmaceuticals (as a diagnostic reagent or therapeutic agent), cosmetics, materials science, and nanotechnology[3][4][5][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fullerenol-C60.